A Study To Evaluate The Treatment Pattern Of Moderate-to-Severe Asthma Patients In China

Trial Identifier: D2287R00198
Sponsor: AstraZeneca
Start Date: March 2024
Primary Completion Date: March 2025
Study Completion Date: March 2025

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China Baoding, China
China Beijing, China
China Changsha, China
China Chengdu, China
China Chongqing, China
China Dingzhou, China
China Hangzhou, China
China Harbin, China
China Hefei, China
China Hohhot, China
China Jinan, China
China Kunming, China
China Liuzhou, China
China Lu an, China
China Luzhou, China
China Nanchang, China
China Nanchong, China
China Qingdao, China
China Quanzhou, China
China Shanghai, China
China Shenzhen, China
China Tianjin, China
China Tiaobingshan, China
China Wenzhou, China
China Wuhan, China
China Xi an, China
China Xiamen, China
China Yongzhou, China
China Zhangjiagang, China
China Zhengzhou, China
China Zigong, China